This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: April 16, 2007
Last updated: November 1, 2016
Last verified: November 2016
This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue (at a dose of 20mg, or a starting dose of 20mg escalating to either 30mg or 40mg), weekly. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Diabetes Mellitus Type 2 Drug: Placebo Drug: Taspoglutide 20mg Drug: Taspoglutide 20mg-30mg Drug: Taspoglutide 20mg-40mg Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients withdrawn because of gastrointestinal effects [ Time Frame: Week 9 ]

Secondary Outcome Measures:
  • Mean changes in 24h blood glucose Area Under the Curve (AUC), Fasting Plasma Glucose (FPG), fructosamine, Hemoglobin A1c (HbA1c), body weight, Adverse Events (AEs), laboratory parameters. [ Time Frame: Week 9 ]

Enrollment: 133
Study Start Date: April 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
sc weekly
Drug: Placebo
sc weekly
Experimental: Taspoglutide 20mg
sc weekly
Drug: Taspoglutide 20mg
sc weekly
Experimental: Taspoglutide 20mg-30mg
sc weekly
Drug: Taspoglutide 20mg-30mg
sc weekly
Experimental: Taspoglutide 20mg-40mg
sc weekly
Drug: Taspoglutide 20mg-40mg
sc weekly


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male,and post-menopausal or surgically sterilized female, patients, 18-75 years of age;
  • type 2 diabetes mellitus, with stable metformin treatment for >=3 months;
  • HbA1c >=7.0% and <=9.5% at screening;
  • stable weight +/-10% for >=3 months before screening.

Exclusion Criteria:

  • type 1 diabetes mellitus;
  • clinically significant gastrointestinal disease;
  • treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months;
  • use of weight-lowering medications in the last 3 months;
  • uncontrolled hypertension;
  • previous exposure to GLP-1 or GLP-1 analogues.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00460941

  Hide Study Locations
United States, Arkansas
Harrisburg, Arkansas, United States, 72432
Hot Springs, Arkansas, United States, 71913
Jonesboro, Arkansas, United States, 72401
United States, California
National City, California, United States, 91950
United States, Florida
Jacksonville, Florida, United States, 32216
United States, Kentucky
Madisonville, Kentucky, United States, 42431
United States, Maryland
Hyattsville, Maryland, United States, 20783
United States, North Carolina
Winston-salem, North Carolina, United States, 27103
United States, Texas
Dallas, Texas, United States, 75230
Dallas, Texas, United States, 75231
United States, Virginia
Richmond, Virginia, United States, 23294
Adelaide, Australia, 5000
Camperdown, Australia, 2050
Besancon, France, 25030
Corbeil Essonnes, France, 91106
Narbonne, France, 11108
Paris, France, 75877
Poitiers, France, 86021
Berlin, Germany, 10115
München, Germany, 80636
Neuss, Germany, 41460
Chihuahua, Mexico, 31238
Culiacan, Mexico, 80020
Monterrey, Mexico, 64410
Tampico, Mexico, 89109
Lima, Peru, 10
Lima, Peru, 31
Lima, Peru, LIMA 29
Puerto Rico
Ponce, Puerto Rico, 00716
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT00460941     History of Changes
Other Study ID Numbers: BC20728
Study First Received: April 16, 2007
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glucagon-Like Peptide 1
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 21, 2017